Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments - Université de Lille Accéder directement au contenu
Article Dans Une Revue La Presse Médicale Année : 2022

Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments

Résumé

In order to explore pituitary adenoma (PA), magnetic resonance imaging (MRI) remains the cornerstone. However, there are some limitations and MRI can be non-conclusive. The development of additional imaging modalities like nuclear medicine explorations may help to confirm PA diagnosis, guide management and follow up. Nuclear medicine uses radiopharmaceuticals for imaging with single photon emission computed tomography (SPECT), or positron emission tomography (PET), coupled to CT scan. Radiopharmaceuticals products target specific cellular elements which allow to explore several biological pathways. Nuclear medicine may also be used for therapeutic purposes and recent developments of approach based on Peptide Receptor Radionuclide Therapy (PRRT) for treatment of aggressive PA and pituitary carcinoma will be reviewed. Several radiotracers have been studied in the context of PA, and the aim of this paper is to discuss their respective performances and clinical interest.
Fichier non déposé

Dates et versions

hal-04222727 , version 1 (29-09-2023)

Identifiants

Citer

Benjamin Chevalier, Arnaud Jannin, Espiard Stephanie, Emilie Merlen, Amandine Beron, et al.. Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments. La Presse Médicale, 2022, La Presse Médicale, 51 (2), pp.104144. ⟨10.1016/j.lpm.2022.104144⟩. ⟨hal-04222727⟩
20 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More